Tadalafil
Hepatocellular Cancer
National Cancer Institute (NCI)Small moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
14 Active assets in the Hepatocellular Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pregabalin Sherief Abd-Elsalam | Phase 4 | BB |
Hydroxychloroquine VA Office of Research and Development | Phase 2 | B |
Tivozanib AVEO Pharmaceuticals, Inc. | Phase 2 | B |
gsk1120212 Second Affiliated Hospital of Guangzhou Medical University | Phase 2 | B |
Tranexamic Acid Tribhuvan University Teaching Hospital, Institute Of Medicine. | Phase 2/3 | B |
View all 27 →
Same molecule, other indications
Tadalafil is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →